Literature DB >> 21522336

2-[4-(Methyl-sulfon-yl)phen-yl]acetonitrile.

Hoong-Kun Fun, Ching Kheng Quah, V Sumangala, D Jagadeesh Prasad, Boja Poojary.   

Abstract

In the title compound, C(9)H(9)NO(2)S, the benzene ring and the acetonitrile group are approximately coplanar, with a C-C-C-C torsion angle of 1.1 (3)° between them. In the crystal, mol-ecules are linked via inter-molecular C-H⋯O hydrogen bonds into layers parallel to (001).

Entities:  

Year:  2011        PMID: 21522336      PMCID: PMC3052001          DOI: 10.1107/S1600536811003837

Source DB:  PubMed          Journal:  Acta Crystallogr Sect E Struct Rep Online        ISSN: 1600-5368


Related literature

For general background to and the biological activity of COX-2 inhibitors, see: Orjales et al. (2008 ▶); Zarghi et al. (2008 ▶); Shah et al. (2010 ▶); Arico et al. (2002 ▶); Davies et al. (2002 ▶); Sawaoka et al. (1998 ▶); Liu et al. (2000 ▶); Pasinetti (2001 ▶); Norman et al. (1995 ▶). For a related structure, see: Charlier et al. (2004 ▶). For bond-length data, see: Allen et al. (1987 ▶).

Experimental

Crystal data

C9H9NO2S M = 195.23 Triclinic, a = 5.5599 (2) Å b = 8.0942 (3) Å c = 10.9006 (4) Å α = 81.162 (2)° β = 85.347 (2)° γ = 74.458 (2)° V = 466.60 (3) Å3 Z = 2 Mo Kα radiation μ = 0.31 mm−1 T = 296 K 0.51 × 0.28 × 0.14 mm

Data collection

Bruker SMART APEXII CCD area-detector diffractometer Absorption correction: multi-scan (SADABS; Bruker, 2009 ▶) T min = 0.810, T max = 0.957 5970 measured reflections 1826 independent reflections 1673 reflections with I > 2σ(I) R int = 0.023

Refinement

R[F 2 > 2σ(F 2)] = 0.038 wR(F 2) = 0.110 S = 1.09 1826 reflections 119 parameters H-atom parameters constrained Δρmax = 0.29 e Å−3 Δρmin = −0.42 e Å−3 Data collection: APEX2 (Bruker, 2009 ▶); cell refinement: SAINT (Bruker, 2009 ▶); data reduction: SAINT; program(s) used to solve structure: SHELXTL (Sheldrick, 2008 ▶); program(s) used to refine structure: SHELXTL; molecular graphics: SHELXTL; software used to prepare material for publication: SHELXTL and PLATON (Spek, 2009 ▶). Crystal structure: contains datablocks global, I. DOI: 10.1107/S1600536811003837/is2671sup1.cif Structure factors: contains datablocks I. DOI: 10.1107/S1600536811003837/is2671Isup2.hkl Additional supplementary materials: crystallographic information; 3D view; checkCIF report
C9H9NO2SZ = 2
Mr = 195.23F(000) = 204
Triclinic, P1Dx = 1.390 Mg m3
Hall symbol: -P 1Mo Kα radiation, λ = 0.71073 Å
a = 5.5599 (2) ÅCell parameters from 4240 reflections
b = 8.0942 (3) Åθ = 2.6–33.0°
c = 10.9006 (4) ŵ = 0.31 mm1
α = 81.162 (2)°T = 296 K
β = 85.347 (2)°Block, colourless
γ = 74.458 (2)°0.51 × 0.28 × 0.14 mm
V = 466.60 (3) Å3
Bruker SMART APEXII CCD area-detector diffractometer1826 independent reflections
Radiation source: fine-focus sealed tube1673 reflections with I > 2σ(I)
graphiteRint = 0.023
φ and ω scansθmax = 26.0°, θmin = 1.9°
Absorption correction: multi-scan (SADABS; Bruker, 2009)h = −6→6
Tmin = 0.810, Tmax = 0.957k = −9→9
5970 measured reflectionsl = −13→13
Refinement on F2Primary atom site location: structure-invariant direct methods
Least-squares matrix: fullSecondary atom site location: difference Fourier map
R[F2 > 2σ(F2)] = 0.038Hydrogen site location: inferred from neighbouring sites
wR(F2) = 0.110H-atom parameters constrained
S = 1.09w = 1/[σ2(Fo2) + (0.054P)2 + 0.1771P] where P = (Fo2 + 2Fc2)/3
1826 reflections(Δ/σ)max = 0.001
119 parametersΔρmax = 0.29 e Å3
0 restraintsΔρmin = −0.42 e Å3
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.
Refinement. Refinement of F2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > 2sigma(F2) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F2 are statistically about twice as large as those based on F, and R- factors based on ALL data will be even larger.
xyzUiso*/Ueq
S10.64766 (8)0.30347 (6)0.36428 (4)0.04502 (19)
O10.6714 (4)0.45775 (18)0.28743 (16)0.0728 (5)
O20.4011 (3)0.2889 (2)0.40261 (19)0.0773 (5)
N11.5750 (4)−0.2897 (2)−0.02043 (19)0.0638 (5)
C11.1353 (3)−0.0135 (2)0.15700 (17)0.0427 (4)
H1A1.2799−0.01140.10810.051*
C21.0162 (3)0.1282 (2)0.21644 (17)0.0429 (4)
H2A1.08010.22460.20800.051*
C30.8008 (3)0.1237 (2)0.28841 (15)0.0365 (4)
C40.7055 (3)−0.0194 (2)0.30170 (17)0.0439 (4)
H4A0.5607−0.02120.35050.053*
C50.8260 (3)−0.1598 (2)0.24231 (18)0.0445 (4)
H5A0.7620−0.25610.25120.053*
C61.0422 (3)−0.1580 (2)0.16938 (15)0.0370 (4)
C71.1679 (4)−0.3160 (2)0.10645 (18)0.0464 (4)
H7A1.2073−0.41670.16940.056*
H7B1.0511−0.33430.05170.056*
C81.3966 (4)−0.3021 (2)0.03441 (18)0.0468 (4)
C90.8180 (4)0.2777 (3)0.4977 (2)0.0586 (5)
H9A0.74820.37320.54330.088*
H9B0.98910.27440.47380.088*
H9C0.81000.17160.54900.088*
U11U22U33U12U13U23
S10.0405 (3)0.0414 (3)0.0506 (3)−0.00199 (19)−0.00442 (19)−0.0129 (2)
O10.1054 (14)0.0367 (8)0.0691 (10)−0.0059 (8)−0.0101 (9)−0.0042 (7)
O20.0381 (8)0.0876 (12)0.1116 (14)−0.0088 (7)0.0091 (8)−0.0496 (11)
N10.0653 (12)0.0591 (11)0.0703 (12)−0.0208 (9)0.0182 (10)−0.0217 (9)
C10.0428 (9)0.0427 (10)0.0458 (10)−0.0169 (7)0.0069 (7)−0.0099 (7)
C20.0466 (10)0.0382 (9)0.0479 (10)−0.0185 (7)0.0028 (8)−0.0079 (7)
C30.0367 (8)0.0361 (8)0.0354 (8)−0.0072 (7)−0.0024 (6)−0.0042 (6)
C40.0390 (9)0.0468 (10)0.0474 (10)−0.0153 (8)0.0042 (7)−0.0070 (8)
C50.0471 (10)0.0393 (9)0.0519 (10)−0.0200 (8)−0.0002 (8)−0.0062 (8)
C60.0395 (9)0.0366 (8)0.0351 (8)−0.0094 (7)−0.0051 (7)−0.0050 (7)
C70.0500 (10)0.0394 (9)0.0516 (11)−0.0119 (8)−0.0004 (8)−0.0123 (8)
C80.0567 (12)0.0381 (9)0.0463 (10)−0.0094 (8)−0.0016 (9)−0.0138 (8)
C90.0550 (12)0.0689 (14)0.0505 (11)−0.0037 (10)−0.0073 (9)−0.0231 (10)
S1—O11.4239 (16)C4—C51.381 (3)
S1—O21.4306 (16)C4—H4A0.9300
S1—C91.755 (2)C5—C61.388 (2)
S1—C31.7657 (17)C5—H5A0.9300
N1—C81.136 (3)C6—C71.519 (2)
C1—C61.385 (2)C7—C81.461 (3)
C1—C21.387 (2)C7—H7A0.9700
C1—H1A0.9300C7—H7B0.9700
C2—C31.383 (2)C9—H9A0.9600
C2—H2A0.9300C9—H9B0.9600
C3—C41.382 (3)C9—H9C0.9600
O1—S1—O2117.73 (12)C4—C5—H5A119.8
O1—S1—C9108.35 (11)C6—C5—H5A119.8
O2—S1—C9108.32 (12)C1—C6—C5119.12 (16)
O1—S1—C3108.95 (9)C1—C6—C7122.56 (16)
O2—S1—C3108.26 (9)C5—C6—C7118.32 (15)
C9—S1—C3104.42 (9)C8—C7—C6113.81 (15)
C6—C1—C2120.95 (16)C8—C7—H7A108.8
C6—C1—H1A119.5C6—C7—H7A108.8
C2—C1—H1A119.5C8—C7—H7B108.8
C3—C2—C1118.95 (16)C6—C7—H7B108.8
C3—C2—H2A120.5H7A—C7—H7B107.7
C1—C2—H2A120.5N1—C8—C7179.0 (2)
C4—C3—C2120.80 (16)S1—C9—H9A109.5
C4—C3—S1119.91 (13)S1—C9—H9B109.5
C2—C3—S1119.28 (13)H9A—C9—H9B109.5
C5—C4—C3119.72 (16)S1—C9—H9C109.5
C5—C4—H4A120.1H9A—C9—H9C109.5
C3—C4—H4A120.1H9B—C9—H9C109.5
C4—C5—C6120.45 (16)
C6—C1—C2—C3−0.3 (3)C2—C3—C4—C5−0.1 (3)
C1—C2—C3—C40.3 (3)S1—C3—C4—C5−179.93 (13)
C1—C2—C3—S1−179.94 (13)C3—C4—C5—C60.0 (3)
O1—S1—C3—C4−145.12 (16)C2—C1—C6—C50.1 (3)
O2—S1—C3—C4−15.97 (18)C2—C1—C6—C7−179.65 (16)
C9—S1—C3—C499.29 (17)C4—C5—C6—C10.0 (3)
O1—S1—C3—C235.06 (17)C4—C5—C6—C7179.80 (16)
O2—S1—C3—C2164.22 (15)C1—C6—C7—C81.1 (3)
C9—S1—C3—C2−80.53 (17)C5—C6—C7—C8−178.67 (16)
D—H···AD—HH···AD···AD—H···A
C5—H5A···O1i0.932.473.384 (2)169
C9—H9B···O2ii0.962.393.343 (3)175
Table 1

Hydrogen-bond geometry (Å, °)

D—H⋯AD—HH⋯ADAD—H⋯A
C5—H5A⋯O1i0.932.473.384 (2)169
C9—H9B⋯O2ii0.962.393.343 (3)175

Symmetry codes: (i) ; (ii) .

  10 in total

1.  A short history of SHELX.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A       Date:  2007-12-21       Impact factor: 2.290

2.  Cyclooxygenase and Alzheimer's disease: implications for preventive initiatives to slow the progression of clinical dementia.

Authors:  G M. Pasinetti
Journal:  Arch Gerontol Geriatr       Date:  2001-08       Impact factor: 3.250

3.  Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line.

Authors:  Sebastien Arico; Sophie Pattingre; Chantal Bauvy; Pierre Gane; Alain Barbat; Patrice Codogno; Eric Ogier-Denis
Journal:  J Biol Chem       Date:  2002-05-08       Impact factor: 5.157

4.  Pharmacophore generation and atom-based 3D-QSAR of novel 2-(4-methylsulfonylphenyl)pyrimidines as COX-2 inhibitors.

Authors:  Ujashkumar A Shah; Hemantkumar S Deokar; Shivajirao S Kadam; Vithal M Kulkarni
Journal:  Mol Divers       Date:  2009-08-11       Impact factor: 2.943

5.  Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo.

Authors:  X H Liu; A Kirschenbaum; S Yao; R Lee; J F Holland; A C Levine
Journal:  J Urol       Date:  2000-09       Impact factor: 7.450

6.  Novel 2-(4-methylsulfonylphenyl)pyrimidine derivatives as highly potent and specific COX-2 inhibitors.

Authors:  Aurelio Orjales; Ramón Mosquera; Beatriz López; Roberto Olivera; Luis Labeaga; M Teresa Núñez
Journal:  Bioorg Med Chem       Date:  2007-12-05       Impact factor: 3.641

Review 7.  Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention.

Authors:  G Davies; L A Martin; N Sacks; M Dowsett
Journal:  Ann Oncol       Date:  2002-05       Impact factor: 32.976

8.  1-[4-(Methylsulfonyl)phenyl]-5-phenyl-1H-pyrazole derivatives.

Authors:  Caroline Charlier; Bernadette Norberg; Laurence Goossens; Jean Pierre Hénichart; François Durant
Journal:  Acta Crystallogr C       Date:  2004-08-11       Impact factor: 1.172

9.  Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice.

Authors:  H Sawaoka; S Kawano; S Tsuji; M Tsujii; E S Gunawan; Y Takei; K Nagano; M Hori
Journal:  Am J Physiol       Date:  1998-06

10.  Structure validation in chemical crystallography.

Authors:  Anthony L Spek
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-01-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.